查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014582

事後緊急避孕藥市場：按產品類型、處方形式、年齡層和分銷管道分類的全球市場預測，2026-2032年

Emergency Contraceptive Pills Market by Product Type, Prescription Type, Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，事後緊急避孕藥市場價值將達到 11.5 億美元，到 2026 年將成長到 12.2 億美元，到 2032 年將達到 18.2 億美元，複合年成長率為 6.76%。

主要市場統計數據
基準年 2025 11.5億美元
預計年份：2026年 12.2億美元
預測年份 2032 18.2億美元
複合年成長率 (%) 6.76%

簡要介紹正在重塑事後緊急避孕藥取得和供應的當代臨床、監管和消費者趨勢。

事後緊急避孕藥領域的格局正在不斷演變，這受到臨床、監管和消費者主導等多方面因素的共同影響。藥理學的進步和臨床指南的更新改變了這些產品在臨床和零售通路中的定位。同時，監管機構和公共衛生部門也不斷調整取得途徑，包括遠端醫療，從而拓寬了提供緊急避孕服務的管道。

監管變化、遠端醫療的擴展和數位商務如何共同改變事後緊急避孕藥在市場上的取得、分銷和競爭地位。

事後緊急避孕藥領域正經歷一場變革，其驅動力包括監管改革、醫療服務路徑的數位化以及消費者期望的不斷變化。監管機構正分階段重新評估非處方藥的監管框架和標籤，以擴大安全獲取途徑；同時，許多醫療系統正在整合遠端醫療服務，以縮短治療時間並在必要時維持臨床監督。此外，線上藥局和零售連鎖店正在打造無縫的購買和配送體驗，在不影響諮詢或安全措施的前提下，加速消費者取得緊急避孕藥的速度。

本研究評估了 2025 年關稅政策轉變如何加速了事後緊急避孕藥。

與關稅實施相關的政策決定將對醫藥供應鏈、籌資策略和產品定價趨勢產生實際的下游影響。 2025年實施的關稅進一步增加了進口藥品原料和成品的成本壓力，促使買家和生產商重新檢視其籌資策略。為此，一些生產商試圖透過加快替代供應商的認證或遷移生產基地來降低進口關稅的影響。同時，有些生產商則自行承擔了額外的成本，以維持在敏感治療領域的零售競爭力。

基於詳細細分的洞察揭示了產品類型、處方格式和年齡層如何影響事後緊急避孕藥的取得、通訊和管道策略。

深入的市場區隔揭示了不同的需求促進因素和獲取管道，需要採取個人化的策略應對措施。基於產品類型，levonorgestrel、米非司酮和醋酸烏利司他的市場動態在臨床適應症、給藥持續時間和監管狀態方面存在差異，這些差異反過來又會影響標籤、消費者指導和分銷選擇。基於處方形式，非處方藥 (OTC) 和處方藥在可近性方面的差異會影響分銷策略、患者諮詢要求和支付方參與度。非處方藥通路需要全面的銷售點教育，而處方藥通路則需要與醫療保健專業人員進行密切合作。

從區域比較的觀點來看，法律規範、文化規範和製造地如何驅動世界各地不同的准入和分銷策略。

區域趨勢正在塑造截然不同的監管方式、供應鏈結構和消費者獲取模式。在美洲，政策辯論和計劃正在加速擴大藥品獲取管道，透過非遠端醫療服務的推廣，建構起由成熟分銷網路支撐的強大零售和電商管道。相較之下，歐洲、中東和非洲（EMEA）地區的監管體系則呈現出複雜多樣的局面，各國政策、文化規範和報銷制度的差異導致藥品獲取途徑各不相同，因此需要製定針對特定區域的監管策略和相關人員參與計劃。

競爭對手行為與策略重點：製造商、非專利生產商和數位新參與企業如何塑造產品准入和分銷生態系統

事後緊急避孕藥市場的主要企業正採取產品系列廣度、銷售管道覆蓋範圍和生產能力相符的策略。成熟的製藥企業利用規模經濟、監管經驗以及與批發商的長期合作關係，維持廣泛的分銷網路。同時，學名藥生產商則專注於成本效益和快速產品上市，只要監管途徑允許。新興企業，包括專業的生技公司和數位健康平台，則致力於打造差異化的服務模式，將遠端醫療處方與一體化的履約和消費者教育結合。

為領導者提供切實可行的建議，以加強供應鏈韌性、擴大數位管道，並使監管策略與以消費者為中心的商業化保持一致。

產業領導者應採取實際措施，平衡醫療服務的可近性、安全性和商業性永續性。首先，他們應實現供應商網路多元化，並投資於供應商合格，以降低因貿易政策變化而加劇的單一來源風險。這包括建構區域製造能力和簽訂長期供應合約。其次，他們應將遠端保健夥伴關係和數位商務能力融入全通路策略，以確保及時取得服務，同時滿足重視隱私和便利性的使用者需求。

概述透明的調查方法，詳細介紹證據來源、相關人員諮詢和基於情境的分析，以得出見解和策略意義。

本分析整合了監管通知、最新臨床指南、供應鏈趨勢報告和公開政策公告，從多個角度提煉出可操作的洞見。主要輸入資料包括監管決策和指導文件、貿易政策公告以及對供應鏈和商業領域領導者的匿名行業訪談，並將這些資訊全面納入對分銷和籌資策略的解讀。次要輸入資料包括關於保存期限和安全性概況的同儕審查臨床文獻，以及用於分析病患就醫通路變化情況的總結數位醫療應用指標。

一份權威的綜合分析報告強調了韌性、監管合規性和以患者為中心的策略，認為這些是支持獲得可靠事後緊急避孕藥。

事後緊急避孕藥的特殊之處在於它兼具臨床緊迫性、政策敏感性和消費者偏好，這不僅為相關人員帶來了機遇，也帶來了責任。隨著法律規範和數位化管道的不斷發展，能夠迅速將臨床證據轉化為安全獲取途徑，同時保持穩健的供應鏈和符合當地文化習慣的溝通方式的機構，將成為最成功的組織。貿易政策、製造地和分銷網路之間的相互作用，凸顯了採購柔軟性和本地夥伴關係關係在不斷變化的環境中維持緊急避孕藥可及性的關鍵作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：事後緊急避孕藥市場：依產品類型分類

  • levonorgestrel
  • 米非司酮
  • 醋酸烏利司他

第9章：依處方箋類型分類的事後緊急避孕藥市場

  • 非處方藥
  • 處方箋

第10章：事後緊急避孕藥市場：依年齡層別分類

  • 15-19歲
  • 20-24歲
  • 25-29歲
  • 超過30

第11章：事後緊急避孕藥市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 診所和計劃生育中心
  • 非營利組織和公共衛生項目

第12章：事後緊急避孕藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：事後緊急避孕藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：事後緊急避孕藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國事後緊急避孕藥市場

第16章：中國事後緊急避孕藥市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Afaxys Pharma LLC
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Ltd
  • CooperSurgical, Inc.
  • Curae Pharma360, Inc.
  • Dr. Reddy's Laboratories Ltd
  • Fuji Pharma Co., Ltd.
  • Glenmark Pharmaceuticals Limited
  • Glenmark Pharmaceuticals Ltd
  • HLL Lifecare Limited
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd
  • Perrigo Company plc
  • Piramal Enterprises Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
Product Code: MRR-43798151BF31

The Emergency Contraceptive Pills Market was valued at USD 1.15 billion in 2025 and is projected to grow to USD 1.22 billion in 2026, with a CAGR of 6.76%, reaching USD 1.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.15 billion
Estimated Year [2026] USD 1.22 billion
Forecast Year [2032] USD 1.82 billion
CAGR (%) 6.76%

A succinct introduction to contemporary clinical, regulatory, and consumer forces reshaping access and delivery of emergency contraceptive pills

The emergent dynamics shaping emergency contraceptive pills are simultaneously clinical, regulatory, and consumer-driven. Advances in pharmacology and evolving clinical guidelines have altered how these products are positioned in clinical practice and retail channels. At the same time, regulatory agencies and public health authorities continue to adjust access pathways, including over-the-counter availability and telehealth-enabled prescribing, which has broadened the range of delivery mechanisms for time-sensitive care.

Consumer behavior is also shifting, as digital health platforms, consumer education campaigns, and greater awareness of reproductive autonomy influence demand patterns. This transition is accompanied by supply-side transformations: manufacturers are adapting formulations, packaging, and distribution to meet rapid-access expectations while navigating procurement and manufacturing constraints. In the coming cycles, stakeholders must balance evidence-based clinical messaging with pragmatic access solutions to ensure safe, timely use and to mitigate stigma that can delay care.

How regulatory shifts, telehealth expansion, and digital commerce are jointly transforming access, distribution, and competitive positioning for emergency contraceptive pills

The landscape for emergency contraceptive pills has experienced transformative shifts driven by regulatory recalibration, digitization of care pathways, and changes in consumer expectations. Regulatory authorities progressively reassess over-the-counter frameworks and labeling to expand safe access, while many health systems are integrating telemedicine pathways to shorten time-to-treatment and preserve clinical oversight where needed. Simultaneously, e-pharmacies and retail chains are creating seamless purchase and fulfillment experiences that accelerate consumer access without compromising counseling and safety safeguards.

On the supply side, formulation innovation and packaging redesigns focus on user-centric features that reduce administration errors and improve discreet access. These transformations have catalyzed competitive repositioning among established manufacturers and newer entrants that prioritize speed-to-shelf and omnichannel distribution. As a result, strategic imperatives now center on regulatory agility, digital channel partnerships, and cross-functional alignment between clinical affairs, commercialization, and supply chain teams to capture emerging opportunities while maintaining patient safety.

Assessing how tariff policy shifts in 2025 intensified supply chain reconfiguration, sourcing diversification, and cost management across emergency contraceptive product channels

Policy decisions regarding tariff implementation have tangible downstream effects on pharmaceutical supply chains, procurement strategies, and product pricing dynamics. Tariffs imposed in 2025 introduced additional cost pressures on imported active pharmaceutical ingredients and finished products, prompting buyers and manufacturers to reassess sourcing strategies. In response, some manufacturers accelerated qualification of alternative suppliers or shifted production footprints to minimize exposure to import duties, while others absorbed incremental costs to preserve retail competitiveness in sensitive therapeutic categories.

These adjustments have emphasized the value of supply chain transparency and contractual agility. Procurement teams increasingly prioritize multi-sourced supplier networks and longer-term supplier relationships that incorporate contingency clauses. Meanwhile, regulatory and trade policy monitoring has become a core competency for commercial planning teams, because tariff volatility can affect inventory policies and cross-border distribution agreements. Overall, the cumulative impact of tariffs in 2025 served as a catalyst for greater vertical integration, nearshoring conversations, and enhanced focus on cost management across manufacturing and distribution nodes.

Deep segmentation-based insights revealing how product type, prescription modality, and age cohorts influence access, messaging, and channel strategy for emergency contraception

Insightful segmentation reveals differentiated demand drivers and access pathways that require tailored strategic responses. Based on Product Type, market dynamics differ among Levonorgestrel, Mifepristone, and Ulipristal Acetate in terms of clinical indications, dosing windows, and regulatory status, which in turn influences labeling, consumer guidance, and distribution choices. Based on Prescription Type, the distinction between Over The Counter and Prescription availability shapes channel strategy, patient counseling requirements, and payer interactions, with OTC pathways demanding robust point-of-sale education and prescription routes requiring integrated clinician engagement.

Age-related segmentation also informs targeted outreach and packaging: Based on Age Group, the cohorts 15-19 Years, 20-24 Years, 25-29 Years, and 30 Years And Above display varying health literacy, purchasing preferences, and privacy expectations. Younger cohorts tend to favor digital-first information channels and discreet fulfillment options, whereas older cohorts may prioritize in-person clinical reassurance and broader product information. Together, these segmentation lenses provide an actionable framework for product managers and patient engagement teams to design differentiated marketing, educational materials, and distribution partnerships that align with clinical constraints and consumer behavior.

Comparative regional perspectives highlighting how regulatory frameworks, cultural norms, and manufacturing footprints drive distinct access and distribution strategies worldwide

Regional dynamics shape regulatory approaches, supply chain architecture, and consumer access models in markedly different ways. In the Americas, policy debates and advocacy have accelerated moves toward broader access with a mix of OTC availability and telehealth services, leading to robust retail and e-commerce channels supported by established distribution networks. In contrast, Europe, Middle East & Africa presents a heterogeneous regulatory mosaic where national policies, cultural norms, and reimbursement systems result in varying access pathways, requiring regionally tailored regulatory strategies and stakeholder engagement plans.

Asia-Pacific combines high-volume manufacturing capabilities with rapidly evolving digital health adoption; this region is simultaneously a major production base and a dynamic market for consumer-facing distribution innovations. These regional variances necessitate differentiated commercial playbooks, where regulatory intelligence, local partnerships, and culturally attuned communication are essential to navigate policy nuance and to optimize product positioning across jurisdictions.

Competitive company behaviors and strategic priorities showing how manufacturers, generics, and digital entrants are shaping product access and distribution ecosystems

Key companies active in emergency contraceptive pills are pursuing strategies that reflect portfolio depth, channel reach, and manufacturing capabilities. Established pharmaceutical manufacturers leverage scale, regulatory experience, and legacy relationships with wholesalers to maintain broad distribution, while generics producers focus on cost efficiency and rapid product launches where regulatory pathways permit. Emerging players, including specialized biotech and digital health platforms, concentrate on differentiated service models that combine telehealth prescribing with integrated fulfillment and consumer education.

Strategic moves observed across company types include investments in formulation enhancements, partnerships with pharmacy chains and online platforms, and selective regional capacity expansions to mitigate trade-related risks. Companies that prioritize cross-functional coordination between clinical affairs, regulatory teams, and commercial units tend to accelerate time-to-market for label updates and channel transitions. Competitive advantage increasingly depends on the ability to balance regulatory compliance, rapid access, and consumer-centric design while protecting margins through operational efficiency and supply chain resilience.

Actionable recommendations for leaders to strengthen supply resilience, expand digital access, and align regulatory strategy with consumer-centered commercialization

Industry leaders should adopt pragmatic measures that balance access, safety, and commercial sustainability. First, diversify supplier networks and invest in supplier qualification to reduce exposure to single-source risks exacerbated by trade policy fluctuations; this includes building regional manufacturing capacity or securing long-term supply agreements. Second, integrate telehealth partnerships and digital commerce capabilities into omnichannel strategies to ensure timely access and to reach cohorts that prioritize privacy and convenience.

Third, align regulatory affairs with commercial planning to expedite label clarifications and OTC transitions where clinically appropriate, while ensuring that product labeling and packaging address real-world use considerations. Fourth, invest in targeted education campaigns that resonate with distinct age cohorts and clinical audiences to reduce misuse and to improve time-to-treatment. Finally, implement advanced inventory and demand sensing practices to maintain service levels during policy-driven supply disruptions, and embed scenario planning into strategic reviews to respond swiftly to evolving trade and regulatory conditions.

A transparent methodological overview describing evidence sources, stakeholder consultations, and scenario-driven analysis used to derive insights and strategic implications

This analysis synthesizes regulatory filings, clinical guidance updates, supply chain trend reporting, and public domain policy announcements to triangulate actionable insights. Primary inputs included regulatory decisions and guidance documents, trade policy notices, and anonymized industry interviews with supply chain and commercial leaders, which together informed interpretation of distribution and sourcing strategies. Secondary inputs encompassed peer-reviewed clinical literature on efficacy windows and safety profiles, as well as aggregated digital health adoption indicators to contextualize changes in patient access channels.

Analytical methods combined qualitative synthesis with scenario-based impact assessment to evaluate implications of policy shifts, supply chain disruptions, and channel evolution. Cross-validation was performed by comparing independent sources and practitioner perspectives to ensure consistency and to surface areas of divergence that warrant closer monitoring. Ethical considerations and patient safety remained central throughout the methodology, and wherever applicable, clinical evidence was cross-checked against authoritative guidance documents to maintain accuracy and relevance.

A conclusive synthesis emphasizing resilience, regulatory alignment, and patient-centered strategies as the pillars for reliable emergency contraceptive access

Emergency contraceptive pills occupy a unique intersection of clinical urgency, policy sensitivity, and consumer preference, creating both opportunities and responsibilities for stakeholders. As regulatory frameworks and digital channels continue to evolve, the most successful organizations will be those that can rapidly translate clinical evidence into safe access pathways while maintaining supply chain robustness and culturally competent communication. The interplay between trade policy, manufacturing locus, and distribution networks underscores the importance of flexibility in sourcing and the value of local partnerships to sustain access under shifting conditions.

Moving forward, decision makers should prioritize interoperability across regulatory, commercial, and clinical domains to respond quickly to changes in policy or public health guidance. By focusing on resilience, consumer-focused design, and regulatory alignment, stakeholders can responsibly expand access while safeguarding product quality and patient outcomes. The strategic choices made now will determine who can reliably deliver timely, safe emergency contraception in a landscape defined by rapid change and heightened public attention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Emergency Contraceptive Pills Market, by Product Type

  • 8.1. Levonorgestrel
  • 8.2. Mifepristone
  • 8.3. Ulipristal Acetate

9. Emergency Contraceptive Pills Market, by Prescription Type

  • 9.1. Over The Counter
  • 9.2. Prescription

10. Emergency Contraceptive Pills Market, by Age Group

  • 10.1. 15-19 Years
  • 10.2. 20-24 Years
  • 10.3. 25-29 Years
  • 10.4. 30 Years And Above

11. Emergency Contraceptive Pills Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Clinics And Family Planning Centers
  • 11.5. Nonprofit And Public Health Programs

12. Emergency Contraceptive Pills Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Emergency Contraceptive Pills Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Emergency Contraceptive Pills Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Emergency Contraceptive Pills Market

16. China Emergency Contraceptive Pills Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Afaxys Pharma LLC
  • 17.6. Amneal Pharmaceuticals, Inc.
  • 17.7. Apotex Inc
  • 17.8. Apotex Inc.
  • 17.9. Aurobindo Pharma Limited
  • 17.10. Bayer AG
  • 17.11. Cipla Ltd
  • 17.12. CooperSurgical, Inc.
  • 17.13. Curae Pharma360, Inc.
  • 17.14. Dr. Reddy's Laboratories Ltd
  • 17.15. Fuji Pharma Co., Ltd.
  • 17.16. Glenmark Pharmaceuticals Limited
  • 17.17. Glenmark Pharmaceuticals Ltd
  • 17.18. HLL Lifecare Limited
  • 17.19. Johnson & Johnson Services, Inc.
  • 17.20. Lupin Ltd
  • 17.21. Perrigo Company plc
  • 17.22. Piramal Enterprises Limited
  • 17.23. Sandoz International GmbH
  • 17.24. Sun Pharmaceutical Industries Ltd.
  • 17.25. Teva Pharmaceutical Industries Ltd
  • 17.26. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY LEVONORGESTREL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY LEVONORGESTREL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY LEVONORGESTREL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY MIFEPRISTONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY MIFEPRISTONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY MIFEPRISTONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY ULIPRISTAL ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY ULIPRISTAL ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY ULIPRISTAL ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 15-19 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 15-19 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 15-19 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 20-24 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 20-24 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 20-24 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 25-29 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 25-29 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 25-29 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 30 YEARS AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 30 YEARS AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY 30 YEARS AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY CLINICS AND FAMILY PLANNING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY CLINICS AND FAMILY PLANNING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY CLINICS AND FAMILY PLANNING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY NONPROFIT AND PUBLIC HEALTH PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY NONPROFIT AND PUBLIC HEALTH PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY NONPROFIT AND PUBLIC HEALTH PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GCC EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GCC EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GCC EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GCC EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GCC EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. G7 EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. G7 EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. G7 EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. G7 EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. G7 EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. NATO EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NATO EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NATO EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NATO EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. NATO EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. UNITED STATES EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. CHINA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA EMERGENCY CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)